Part 3.8 / M22, M23, M29

Index No

►M18  Chemical name ◄

EC No

CAS No

Classification

Labelling

►M18  Specific Conc. Limits, M-factors and ATEs (*1)  ◄

Notes

Hazard Class and

Category Code(s)

Hazard statement Code(s)

Pictogram, Signal Word Code(s)

Hazard statement Code(s)

Suppl. Hazard statement Code(s)

▼M16

006-069-00-3

thiophanate-methyl (ISO);

dimethyl (1,2-phenylenedicarbamothioyl)biscarbamate;

dimethyl 4,4′-(o-phenylene)bis(3-thioallophanate)

245-740-7

23564-05-8

Carc. 2

Muta. 2

Acute Tox. 4

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H341

H332

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H341

H332

H317

H410

inhalation: ATE = 1,7 mg/l

(dusts and mists)

M = 10

M = 10

006-076-00-1

mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt

—

8018-01-7

Carc. 2

Repr. 1B

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H360D

H373 (thyroid, nervous system)

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H351

H360D

H373 (thyroid, nervous system)

H317

H410

M = 10

M = 10

007-004-00-1

nitric acid …% [C > 70 %]

231-714-2

7697-37-2

Ox. Liq. 2

Acute Tox. 1

Skin Corr. 1A

H272

H330

H314

GHS03

GHS06

GHS05

Dgr

H272

H330

H314

EUH071

Ox. Liq. 2; H272: C ≥ 99 %

Ox. Liq. 3; H272: 70 % ≤ C < 99 %

B

007-030-00-3

nitric acid …% [C ≤ 70 %]

231-714-2

7697-37-2.

Ox. Liq. 3

Acute Tox. 3

Skin Corr. 1A

H272

H331

H314

GHS03

GHS06

GHS05

Dgr

H272

H331

H314

EUH071

Ox. Liq. 3; H272: C ≥ 65 %

inhalation: ATE = 2,65 mg/L (vapours)

Skin Corr. 1A; H314: C ≥ 20 %

Skin Corr. 1B; H314: 5 % ≤ C < 20 %

B

014-018-00-1

octamethylcyclotetrasiloxane;

[D4]

209-136-7

556-67-2

Repr. 2

Aquatic Chronic 1

H361f ***

H410

GHS08

GHS09

Wng

H361f ***

H410

M = 10

014-048-00-5

silicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Carc. 1B

H350i

GHS08

Dgr

H350i

014-049-00-0

trimethoxyvinylsilane; trimethoxy(vinyl)silane

220-449-8

2768-02-7

Skin Sens. 1B

H317

GHS07

Wng

H317

014-050-00-6

tris(2-methoxyethoxy)vinylsilane;

6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane

213-934-0

1067-53-4

Repr. 1B

H360FD

GHS08

Dgr

H360FD

015-113-00-0

tolclofos-methyl (ISO);

O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate

260-515-3

57018-04-9

Skin Sens. 1B

Aquatic Acute 1

Aquatic Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

M = 1

M = 1

015-134-00-5

pirimiphos-methyl (ISO);

O-[2-(diethylamino)-6-methylpyrimidin-4-yl] O,O-dimethyl phosphorothioate

249-528-5

29232-93-7

Acute Tox. 4

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H372 (nervous system)

H400

H410

GHS07

GHS08

GHS09

Dgr

H302

H372 (nervous system)

H410

oral: ATE = 1414 mg/kg bw

M = 1000

M = 1000

015-181-00-1

phosphine

232-260-8

7803-51-2

Flam. Gas 1

Press. Gas

Acute Tox. 1

Skin Corr. 1B

Aquatic Acute 1

H220

H330

H314

H400

GHS02

GHS04

GHS06

GHS05

GHS09

Dgr

H220

H330

H314

H400

inhalation:

ATE = 10 ppmV (gases)

U

015-189-00-5

phenyl bis(2,4,6-trimethylbenzoyl)-phosphine oxide

423-340-5

162881-26-7

Skin Sens. 1A

Aquatic Chronic 4

H317

H413

GHS07

Wng

H317

H413

016-098-00-3

dimethyl disulphide

210-871-0

624-92-0

Flam. Liq. 2

Acute Tox. 3

Acute Tox. 3

STOT SE 3

STOT SE 1

Eye Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H225

H331

H301

H336

H370 (upper respiratory tract, inhalation)

H319

H317

H400

H410

GHS02

GHS06

GHS08

GHS09

Dgr

H225

H331

H301

H336

H370 (upper respiratory tract, inhalation)

H319

H317

H410

inhalation: ATE = 5 mg/L (vapours)

oral: ATE = 190 mg/kg bw

M = 1

M = 10

►C6  022-006-00-2 ◄

titanium dioxide;

[in powder form containing 1 % or more of particles with aerodynamic diameter ≤ 10 μm]

236-675-5

13463-67-7

Carc. 2

H351 (inhalation)

GHS08

Wng

H351 (inhalation)

V, W, 10

027-001-00-9

cobalt

231-158-0

7440-48-4

Carc. 1B

Muta. 2

Repr. 1B

Resp. Sens. 1

Skin Sens. 1

Aquatic Chronic 4

H350

H341

H360F

H334

H317

H413

GHS08

Dgr

H350

H341

H360F

H334

H317

H413

028-007-00-4

trinickel disulfide;

nickel subsulfide; [1]

heazlewoodite [2]

234-829-6 [1]

- [2]

12035-72-2 [1]

12035-71-1 [2]

Carc. 1A

Muta. 2

Acute Tox. 3

STOT RE 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H350i

H341

H331

H372**

H317

H400

H410

GHS08

GHS06

GHS09

Dgr

H350i

H341

H331

H372**

H317

H410

inhalation:

ATE = 0,92 mg/l

(dusts or mists)

028-018-00-4

nickel bis(sulfamidate);

nickel sulfamate

237-396-1

13770-89-3

Carc. 1A

Muta. 2

Repr. 1B

Acute Tox. 4

STOT RE 1

Resp. Sens. 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H350i

H341

H360D***

H302

H372**

H334

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H350i

H341

H360D***

H302

H372**

H334

H317

H410

oral: ATE = 853 mg/kg bw (anhydrate)

oral: ATE = 1098 mg/kg bw (tetrahydrate)

STOT RE 1;

H372: C ≥ 1 %

STOT RE 2;

H373: 0,1 % ≤ C < 1 %

Skin Sens. 1;

H317: C ≥ 0,01 %

M = 1

029-002-00-X

dicopper oxide;

copper (I) oxide

215-270-7

1317-39-1

Acute Tox. 4

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H332

H302

H318

H410

inhalation: ATE = 3,34 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 100

M = 10

029-015-00-0

copper thiocyanate

214-183-1

1111-67-7

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

EUH032

M = 10

M = 10

029-016-00-6

copper(II) oxide

215-269-1

1317-38-0

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 100

M = 10

029-017-00-1

dicopper chloride trihydroxide

215-572-9

1332-65-6

Acute Tox. 4

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H332

H301

H400

H410

GHS06

GHS09

Dgr

H332

H301

H410

inhalation: ATE = 2,83 mg/l (dusts or mists)

oral: ATE = 299 mg/kg bw

M = 10

M = 10

029-018-00-7

tetracopper hexahydroxide sulphate; [1]

tetracopper hexahydroxide sulphate hydrate [2]

215-582-3 [1]

215-582-3 [2]

1333-22-8 [1]

12527-76-3 [2]

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H302

H400

H410

GHS07

GHS09

Wng

H302

H410

oral: ATE = 500 mg/kg bw

M = 10

M = 10

029-019-01-X

copper flakes (coated with aliphatic acid)

—

—

Acute Tox. 3

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H331

H302

H319

H400

H410

GHS06

GHS09

Dgr

H331

H302

H319

H410

inhalation: ATE = 0,733 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 10

M = 10

029-020-00-8

copper(II) carbonate—copper(II) hydroxide (1:1)

235-113-6

12069-69-1

Acute Tox. 4

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H319

H400

H410

GHS07

GHS09

Wng

H332

H302

H319

H410

inhalation: ATE = 1,2 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 10

M = 10

029-021-00-3

copper dihydroxide;

copper(II) hydroxide

243-815-9

20427-59-2

Acute Tox. 2

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H330

H302

H318

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H318

H410

inhalation: ATE = 0,47 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 10

M = 10

029-022-00-9

bordeaux mixture;

reaction products of copper sulphate with calcium dihydroxide

—

8011-63-0

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H332

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H332

H318

H410

inhalation: ATE = 1,97 mg/l (dusts or mists)

M = 10

M = 1

029-023-00-4

copper sulphate pentahydrate

231-847-6

7758-99-8

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H302

H318

H410

oral: ATE = 481 mg/kg bw

M = 10

M = 1

029-024-00-X

granulated copper;

[particle length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm]

231-159-6

7440-50-8

Aquatic Chronic 2

H411

GHS09

H411

029-025-00-5

bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O’)copper;

bis(N-cyclohexyl-diazenium-dioxy)-copper;

[Cu-HDO]

239-703-4

312600-89-8

15627-09-5

Flam. Sol. 1

Acute Tox. 4

STOT RE 2

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H228

H302

H373 (liver)

H318

H400

H410

GHS02

GHS07

GHS08

GHS05

GHS09

Dgr

H228

H302

H373(liver)

H318

H410

oral: ATE = 360 mg/kg bw

M = 1

M = 1

050-021-00-4

dichlorodioctylstannane

222-583-2

3542-36-7

Repr. 1B

Acute Tox. 2

STOT RE 1

Aquatic Chronic 3

H360D

H330

H372 **

H412

GHS08

GHS06

Dgr

H360D

H330

H372 **

H412

Repr. 1B; H360 D: C ≥ 0,03 %

inhalation: ATE = 0,098 mg/L (dusts or mists)

050-027-00-7

2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE]

239-622-4

15571-58-1

Repr. 1B

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H372 (immune system)

H400

H410

GHS08

GHS09

Dgr

H360D

H372 (immune system)

H410

050-031-00-9

dioctyltin dilaurate; [1]

stannane, dioctyl-, bis(coco acyloxy) derivs. [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Repr. 1B

STOT RE 1

H360D

H372 (immune system)

GHS08

Dgr

H360D

H372 (immune system)

080-012-00-0

methylmercuric chloride

204-064-2

115-09-3

Carc. 2

Repr. 1A

Lact.

Acute Tox. 2

Acute Tox. 2

Acute Tox. 2

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H360Df

H362

H330

H310

H300

H372 (nervous system, kidneys)

H400

H410

GHS08

GHS06

GHS09

Dgr

H351

H360Df

H362

H330

H310

H300

H372 (nervous system, kidneys)

H410

inhalation: ATE = 0,05 mg/l (dusts or mists)

dermal: ATE = 50 mg/kg bw

oral: ATE = 5 mg/kg bw

1

601-029-00-7

dipentene;

limonene [1]

(S)-p-mentha-1,8-diene; l-limonene [2]

trans-1-methyl-4-(1-methylvinyl)cyclohexene; [3]

(±)-1-methyl-4-(1-methylvinyl)cyclohexene [4]

205-341-0 [1]

227-815-6 [2]

229-977-3 [3]

231-732-0 [4]

138-86-3 [1]

5989-54-8 [2]

6876-12-6 [3]

7705-14-8 [4]

Flam. Liq. 3

Skin Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H226

H315

H317

H400

H410

GHS02

GHS07

GHS09

Wng

H226

H315

H317

H410

C

601-090-00-X

benzo[rst]pentaphene

205-877-5

189-55-9

Carc. 1B

Muta. 2

H350

H341

GHS08

Dgr

H350

H341

601-091-00-5

dibenzo[b,def]chrysene;

dibenzo[a,h]pyrene

205-878-0

189-64-0

Carc. 1B

Muta. 2

H350

H341

GHS08

Dgr

H350

H341

601-092-00-0

dibenzo[def,p]chrysene;

dibenzo[a,l]pyrene

205-886-4

191-30-0

Carc. 1B

Muta. 2

H350

H341

GHS08

Dgr

H350

H341

Carc. 1B; H350: C ≥ 0,001 %

601-093-00-6

1,4-dimethylnaphthalene

209-335-9

571-58-4

Acute Tox. 4

Asp. Tox. 1

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 3

H302

H304

H319

H400

H412

GHS07

GHS08

GHS09

Dgr

H302

H304

H319

H410

oral: ATE = 1 300 mg/kg bw

M = 1

601-094-00-1

1-isopropyl-4-methylbenzene;

p-cymene

202-796-7

99-87-6

Flam. Liq. 3

Acute Tox. 3

Asp. Tox. 1

Aquatic Chronic 2

H226

H331

H304

H411

GHS02

GHS06

GHS08

GHS09

Dgr

H226

H331

H304

H411

inhalation: ATE = 3 mg/l (vapours)

601-095-00-7

p-mentha-1,3-diene; 1-isopropyl-4-methylcyclohexa-1,3-diene;

alpha-terpinene

202-795-1

99-86-5

Flam. Liq. 3

Acute Tox. 4

Skin Sens. 1

Asp. Tox. 1

Aquatic Chronic 2

H226

H302

H317

H304

H411

GHS02

GHS07

GHS08

GHS09

Dgr

H226

H302

H317

H304

H411

oral: ATE = 1 680 mg/kg bw

601-096-00-2

(R)-p-mentha-1,8-diene;

d-limonene

227-813-5

5989-27-5

Flam. Liq. 3

Skin Irrit. 2

Skin Sens. 1B

Asp. Tox. 1

Aquatic Acute 1

Aquatic Chronic 3

H226

H315

H317

H304

H400

H412

GHS02

GHS07

GHS08

GHS09

Dgr

H226

H315

H317

H304

H410

M = 1

602-110-00-X

tetrafluoroethylene

204-126-9

116-14-3

Carc. 1B

H350

GHS08

Dgr

H350

603-023-00-X

ethylene oxide;

oxirane

200-849-9

75-21-8

Flam. Gas 1

Press. Gas

Carc. 1B

Muta. 1B

Repr. 1B

Acute Tox. 3

Acute Tox. 3

STOT SE 3

STOT SE 3

STOT RE 1

Skin Corr. 1

Eye Dam. 1

H220

H350

H340

H360Fd

H331

H301

H335

H336

H372 (nervous system)

H314

H318

GHS02

GHS08

GHS06

GHS05

Dgr

H220

H350

H340

H360Fd

H331

H301

H335

H336

H372 (nervous system)

H314

inhalation: ATE = 700ppm (gases)

oral: ATE = 100 mg/kg bw

U

603-024-00-5

1,4-dioxane

204-661-8

123-91-1

Flam. Liq. 2

Carc. 1B

STOT SE 3

Eye Irrit. 2

H225

H350

H335

H319

GHS02

GHS08

GHS07

Dgr

H225

H350

H335

H319

EUH019

EUH066

D

603-065-00-9

m-bis(2,3-epoxypropoxy)benzene;

resorcinol diglycidyl ether

202-987-5

101-90-6

Carc. 1B

Muta. 2

Acute Tox. 3

Acute Tox. 4

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

Aquatic Chronic 3

H350

H341

H311

H302

H315

H319

H317

H412

GHS08

GHS06

Dgr

H350

H341

H311

H302

H315

H319

H317

H412

dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw

603-066-00-4

7-oxa-3-oxiranylbicyclo[4.1.0]heptane; 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide

203-437-7

106-87-6

Carc. 1B

Muta. 2

Repr. 1B

Acute Tox. 3

Acute Tox. 4

H350

H341

H360F

H331

H302

GHS08

GHS06

Dgr

H350

H341

H360F

H331

H302

inhalation: ATE = 0,5 mg/l (dusts or mists)

oral: ATE = 1 847 mg/kg bw

603-098-00-9

2-phenoxyethanol

204-589-7

122-99-6

Acute Tox. 4

STOT SE 3

Eye Dam. 1

H302

H335

H318

GHS05

GHS07

Dgr

H302

H335

H318

oral:

ATE = 1 394 mg/kg bw

603-236-00-8

ethanol, 2,2’-iminobis-, N-(C13-15-branched and linear alkyl) derivs.

308-208-6

97925-95-6

Repr. 1B

H360D

GHS08

Dgr

H360D

603-237-00-3

ipconazole (ISO);

(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol

—

125225-28-7

115850-69-6

115937-89-8

Repr. 1B

Acute Tox. 4

STOT RE 2

Aquatic Chronic 1

H360D

H302

H373 (eyes, skin, liver)

H410

GHS08

GHS07

GHS09

Dgr

H360D

H302

H373 (eyes, skin, liver)

H410

oral: ATE = 500 mg/kg bw

M = 100

603-238-00-9

bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme

205-594-7

143-24-8

Repr. 1B

H360FD

GHS08

Dgr

H360FD

603-239-00-4

paclobutrazol (ISO);

(2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol

—

76738-62-0

Repr. 2

Acute Tox. 4

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H332

H302

H319

H400

H410

GHS08

GHS07

GHS09

Wng

H361d

H332

H302

H319

H410

inhalation: ATE = 3,13 mg/L (dusts or mists)

oral: ATE = 490 mg/kg bw

M = 10

M = 10

603-240-00-X

2,2-bis(bromomethyl)propane-1,3-diol

221-967-7

3296-90-0

Carc. 1B

Muta. 1B

H350

H340

GHS08

Dgr

H350

H340

603-241-00-5

geraniol;

(2E)-3,7-dimethylocta-2,6-dien-1-ol

203-377-1

106-24-1

Skin Sens. 1

H317

GHS07

Wng

H317

604-095-00-5

6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol;

[DBMC]

204-327-1

119-47-1

Repr. 1B

H360F

GHS08

Dgr

H360F

605-005-00-7

metaldehyde (ISO);

2,4,6,8-tetramethyl-1,3,5,7-tetraoxacyclooctane

203-600-2

108-62-3

Flam. Sol. 2

Repr. 2

Acute Tox. 3

Aquatic Chronic 3

H228

H361f

H301

H412

GHS02

GHS08

GHS06

Dgr

H228

H361f

H301

H412

oral: ATE = 283 mg/kg bw

605-041-00-3

2-(4-tert-butylbenzyl)propionaldehyde

201-289-8

80-54-6

Repr. 1B

H360Fd

GHS08

Dgr

H360Fd

606-004-00-4

4-methylpentan-2-one; isobutyl methyl ketone

203-550-1

108-10-1

Flam. Liq. 2

Carc. 2

Acute Tox. 4

STOT SE 3

Eye Irrit. 2

H225

H351

H332

H336

H319

GHS02

GHS07

GHS08

Dgr

H225

H351

H332

H336

H319

EUH066

inhalation: ATE = 11 mg/l (vapours)

606-047-00-9

2-benzyl-2-dimethylamino-4'-morpholinobutyrophenone

404-360-3

119313-12-1

Repr. 1B

Aquatic Acute 1

Aquatic Chronic 1

H360D

H400

H410

GHS08

GHS09

Dgr

H360D

H410

606-152-00-X

(5-chloro-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxy-o-tolyl)methanone; pyriofenone

—

688046-61-9

Carc. 2

Aquatic Chronic 1

H351

H410

GHS08

GHS09

Wng

H351

H410

M = 1

607-177-00-9

tribenuron-methyl (ISO);

methyl 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylcarbamoylsulfamoyl]benzoate

401-190-1

101200-48-0

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H373

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H373

H317

H410

M = 100

M = 100

607-232-00-7

pyridate (ISO);

O-(6-chloro-3-phenylpyridazin-4-yl) S-octyl thiocarbonate

259-686-7

55512-33-9

Acute Tox. 4

Skin Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H315

H317

H400

H410

GHS07

GHS09

Wng

H302

H315

H317

H410

oral: ATE = 500 mg/kg bw

M = 1

M = 10

607-247-00-9

dodecyl methacrylate

205-570-6

142-90-5

STOT SE 3

H335

GHS07

Wng

H335

STOT SE 3; H335: C ≥ 10 %

607-256-00-8

azoxystrobin (ISO);

methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate

—

131860-33-8

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H331

H400

H410

GHS06

GHS09

Dgr

H331

H410

inhalation:

ATE = 0,7 mg/L (dusts or mists)

M = 10

M = 10

607-314-00-2

ethofumesate (ISO);

(RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate

247-525-3

26225-79-6

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1

M = 1

607-421-00-4

cypermethrin (ISO);

α-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; cypermethrin cis/trans +/- 40/60

257-842-9

52315-07-8

Acute Tox. 4

Acute Tox. 4

STOT SE 3

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H335

H373 (nervous system)

H400

H410

GHS07

GHS08

GHS09

Wng

H332

H302

H335

H373 (nervous system)

H410

oral; ATE = 500 mg/kg bw

inhalation; ATE = 3,3 mg/l (dusts or mists)

M = 100000

M = 100000

607-424-00-0

trifloxystrobin (ISO); methyl (E)-methoxyimino-{(E)-α-[1-(α,α,α-trifluoro-m-tolyl)ethylideneaminooxy]-o-tolyl}acetate

—

141517-21-7

Lact.

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H362

H317

H400

H410

GHS07

GHS09

Wng

H362

H317

H410

M = 100

M = 10

607-434-00-5

mecoprop-P (ISO) [1] and its salts;

(R)-2-(4-chloro-2-methylphenoxy)propionic acid [1] and its salts

240-539-0 [1]

16484-77-8 [1]

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H302

H318

H410

oral: ATE = 431 mg/kg bw

M = 10

M = 10

607-733-00-0

cyflumetofen (ISO);

2-methoxyethyl (RS)-2-(4-tert-butylphenyl)-2-cyano-3-oxo-3-(α,α,α-trifluoro-o-tolyl)propionate

—

400882-07-7

Carc. 2

Skin Sens. 1A

H351

H317

GHS08

GHS07

Wng

H351

H317

607-737-00-2

diisohexyl phthalate

276-090-2

71850-09-4

Repr. 1B

H360FD

GHS08

Dgr

H360FD

607-738-00-8

MCPA-thioethyl (ISO);

S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate

246-831-4

25319-90-8

Acute Tox. 4

STOT RE. 2

Aquatic Acute 1 Aquatic Chronic 1

H302

H373 (liver)

H400

H410

GHS07

GHS08

GHS09

Wng

H302

H373 (liver)

H410

oral: ATE = 450 mg/kg bw

M = 10

M = 10

607-740-00-9

diisooctyl phthalate

248-523-5

27554-26-3

Repr. 1B

H360FD

GHS08

Dgr

H360FD

607-741-00-4

4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one; flupyradifurone

—

951659-40-8

Acute Tox. 4

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H302

H373 (muscle)

H400

H410

GHS07

GHS08

GHS09

Wng

H302

H373 (muscle)

H410

oral: ATE = 500 mg/kg bw

M = 10

M = 10

607-742-00-X

thiencarbazone-methyl (ISO);

methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophene-3-carboxylate

—

317815-83-1

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1000

M = 1000

607-743-00-5

L-(+)-lactic acid;

(2S)-2-hydroxypropanoic acid

201-196-2

79-33-4

Skin Corr. 1C

Eye Dam. 1

H314

H318

GHS05

Dgr

H314

EUH071

607-744-00-0

2-methoxyethyl acrylate

221-499-3

3121-61-7

Flam. Liq. 3

Muta. 2

Repr. 1B

Acute Tox. 3

Acute Tox. 4

Skin Corr. 1C

Eye Dam. 1

Skin Sens. 1

H226

H341

H360FD

H331

H302

H314

H318

H317

GHS02

GHS05

GHS06

GHS08

Dgr

H226

H341

H360FD

H331

H302

H314

H317

EUH071

inhalation: ATE = 2,7 mg/L (vapours)

oral: ATE = 404 mg/kg bw

607-745-00-6

glyoxylic acid …%

206-058-5

298-12-4

Eye Dam. 1

Skin Sens. 1B

H318

H317

GHS05

GHS07

Dgr

H318

H317

B

607-746-00-1

sodium N-(hydroxymethyl)glycinate;

[formaldehyde released from sodium N-(hydroxymethyl)glycinate]

274-357-8

70161-44-3

Carc. 1B

Muta. 2

Acute Tox. 4

Acute Tox. 4

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

H350

H341

H332

H302

H335

H315

H319

H317

GHS08

GHS07

Dgr

H350

H341

H332

H302

H335

H315

H319

H317

inhalation: ATE = 3 mg/L (dusts or mists)

oral: ATE = 1100 mg/kg bw

8

9

607-747-00-7

2,2-dibromo-2-cyanoacetamide; [DBNPA]

233-539-7

10222-01-2

Acute Tox. 2

Acute Tox. 3

STOT RE 1

Skin Irrit. 2

Eye Dam. 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H330

H301

H372 (respiratory tract) (inhalation)

H315

H318

H317

H400

H410

GHS06

GHS08

GHS05

GHS09

Dgr

H330

H301

H372 (respiratory tract) (inhalation)

H315

H318

H317

H410

inhalation: ATE = 0,24 mg/l (dusts or mists)

oral: ATE = 118 mg/kg bw

M = 1

M = 1

607-748-00-2

[S-(Z,E)]-5-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)-3-methylpenta-2,4-dienoic acid;

S-abscisic acid

244-319-5

21293-29-8

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1

M = 1

607-749-00-8

methyl salicylate

204-317-7

119-36-8

Repr. 2

Acute Tox. 4

Skin Sens. 1B

Aquatic Chronic 3

H361d

H302

H317

H412

GHS07

GHS08

Wng

H361d

H302

H317

H412

oral: ATE = 890 mg/kg bw

607-750-00-3

citric acid

201-069-1

77-92-9

Eye Irrit. 2

STOT SE 3

H319

H335

GHS07

Wng

H319

H335

607-751-00-9

ethametsulfuron-methyl (ISO);

methyl 2-({[4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)benzoate

—

97780-06-8

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H319

H400

H410

GHS07

GHS09

Wng

H319

H410

M = 1 000

M = 100

607-752-00-4

trinexapac-ethyl (ISO);

ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate

—

95266-40-3

STOT RE 2

Skin Sens. 1B

Aquatic Chronic 1

H373 (gastrointestinal tract)

H317

H410

GHS08

GHS07

GHS09

Wng

H373 (gastrointestinal tract)

H317

H410

M = 1

607-753-00-X

(3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide

—

78821-43-9

Aquatic Chronic 4

H413

H413

607-754-00-5

benzyl salicylate

204-262-9

118-58-1

Skin Sens. 1B

H317

GHS07

Wng

H317

607-755-00-0

(RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate;

tolpyralate

—

1101132-67-5

Carc. 2

Repr. 2

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H361fd

H373 (eye)

H400

H410

GHS08

GHS09

Wng

H351

H361fd

H373 (eye)

H410

M = 10

M = 100

608-039-00-0

2-phenylhexanenitrile

423-460-8

3508-98-3

Acute Tox. 4

Aquatic Chronic 2

H302

H411

GHS07

GHS09

Wng

H302

H411

oral:

ATE = 500 mg/kg bw

608-058-00-4

esfenvalerate (ISO);

(S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate

—

66230-04-4

Acute Tox. 3

Acute Tox. 3

STOT SE 1

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H331

H301

H370 (nervous system)

H373

H317

H400

H410

GHS06

GHS08

GHS09

Dgr

H331

H301

H370 (nervous system)

H373

H317

H410

oral; ATE = 88,5 mg/kg bw

inhalation; ATE = 0,53 mg/l (dusts or mists)

M = 10 000

M = 10 000

608-069-00-4

fludioxonil (ISO); 4-(2,2-difluoro-1,3-benzodioxol-4-yl)-1H-pyrrole-3-carbonitrile

—

131341-86-1

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1

M = 10

609-041-00-4

2,4-dinitrophenol

200-087-7

51-28-5

Acute Tox. 3 *

Acute Tox. 3

Acute Tox. 2

STOT RE 1

Aquatic Acute 1

H331

H311

H300

H372

H400

GHS06

GHS08

GHS09

Dgr

H331

H311

H300

H372

H400

dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw

609-064-00-X

mesotrione (ISO);

2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione

—

104206-82-8

Repr. 2

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H373 (eyes, nervous system)

H400

H410

GHS08

GHS09

Wng

H361d

H373 (eyes, nervous system)

H410

M = 10

M = 10

611-181-00-6

potassium (oxido-NNO-azoxy)cyclohexane;

cyclohexylhydroxydiazene 1-oxide, potassium salt;

[K-HDO]

—

66603-10-9

Flam. Sol. 1

Acute Tox. 3

STOT RE 2

Skin Irrit. 2

Eye Dam. 1

Aquatic Chronic 2

H228

H301

H373 (liver)

H315

H318

H411

GHS02

GHS06

GHS08

GHS05

GHS09

Dgr

H228

H301

H373 (liver)

H315

H318

H411

oral: ATE = 136 mg/kg bw

612-067-00-9

3-aminomethyl-3,5,5-trimethylcyclohexylamine

220-666-8

2855-13-2

Acute Tox. 4

Skin Corr. 1B

Eye Dam. 1

Skin Sens. 1A

H302

H314

H318

H317

GHS05

GHS07

Dgr

H302

H314

H317

oral: ATE = 1 030 mg/kg bw

Skin Sens. 1A; H317: C ≥ 0,001 %

612-252-00-4

imidacloprid (ISO);

(E)-1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylideneamine;

(2E)-1-[(6-chloropyridin-3-yl) methyl]-N-nitroimidazolidin-2-imine

428-040-8

138261-41-3

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H301

H400

H410

GHS06

GHS09

Dgr

H301

H410

oral: ATE = 131 mg/kg bw

M = 100

M = 1 000

612-294-00-3

mecetronium etilsulfate;

N-ethyl-N,N-dimethylhexadecan-1-aminium ethyl sulfate;

mecetronium ethyl sulphate;

[MES]

221-106-5

3006-10-8

Skin Corr. 1

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H314

H318

H400

H410

GHS05

GHS09

Dgr

H314

H410

EUH071

M = 100

M = 1000

613-048-00-8

carbendazim (ISO); methyl benzimidazol-2-ylcarbamate

234-232-0

10605-21-7

Muta. 1B

Repr. 1B

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H340

H360FD

H317

H400

H410

GHS07

GHS08

GHS09

Dgr

H340

H360FD

H317

H410

M = 10

M = 10

613-054-00-0

thiabendazole (ISO);

2-(thiazol-4-yl)benzimidazole

205-725-8

148-79-8

Aquatic Acute 1 Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1

M = 1

613-102-00-0

dimethomorph (ISO); (E,Z)-4-(3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acryloyl)morpholine

404-200-2

110488-70-5

Repr. 1B

Aquatic Chronic 2

H360F

H411

GHS08

GHS09

Dgr

H360F

H411

613-111-00-X

1,2,4-triazole

206-022-9

288-88-0

Repr. 1B

Acute Tox. 4

Eye Irrit. 2

H360FD

H302

H319

GHS08

GHS07

Dgr

H360FD

H302

H319

oral: ATE = 1 320 mg/kg bw

613-112-00-5

octhilinone (ISO);

2-octyl-2H-isothiazol-3-one; [OIT]

247-761-7

26530-20-1

Acute Tox. 2

Acute Tox. 3

Acute Tox. 3

Skin Corr. 1

Eye Dam. 1

Skin Sens. 1A

Aquatic Acute 1 Aquatic Chronic 1

H330

H311

H301

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H311

H301

H314

H317

H410

EUH071

inhalation: ATE = 0,27 mg/L (dusts or mists)

dermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bw

Skin Sens. 1A; H317: C ≥ 0,0015 %

M = 100

M = 100

613-115-00-1

hymexazol (ISO);

3-hydroxy-5-methylisoxazole

233-000-6

10004-44-1

Repr. 2

Acute Tox. 4

Eye Dam. 1

Skin Sens. 1

Aquatic Chronic 2

H361d

H302

H318

H317

H411

GHS08

GHS07

GHS05

GHS09

Dgr

H361d

H302

H318

H317

H411

oral: ATE = 1600 mg/kg bw

613-125-00-6

hexythiazox (ISO);

trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide

—

78587-05-0

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1

M = 1

613-166-00-X

flumioxazin (ISO);

N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboximide

—

103361-09-7

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H400

H410

GHS08

GHS09

Wng

H361d

H410

M = 1 000

M = 1 000

613-202-00-4

pymetrozine (ISO);

(E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one

—

123312-89-0

Carc. 2

Repr. 2

Aquatic Chronic 1

H351

H361fd

H410

GHS08

GHS09

Wng

H351

H361fd

H410

M = 1

613-208-00-7

imazamox (ISO);

(RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid

—

114311-32-9

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H400

H410

GHS08

GHS09

Wng

H361d

H410

M = 10

M = 10

613-259-00-5

imiprothrin (ISO);

reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate

428-790-6

72963-72-5

Carc. 2

Acute Tox. 4

Acute Tox. 4

STOT SE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H332

H302

H371 (nervous system; oral, inhalation)

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H332

H302

H371 (nervous system; oral, inhalation)

H410

inhalation: ATE = 1,4 mg/L (dusts or mists)

oral: ATE = 550 mg/kg bw

M = 10

M = 10

613-267-00-9

thiamethoxam (ISO);

3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine

428-650-4

153719-23-4

Repr. 2

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H361fd

H302

H400

H410

GHS07

GHS08

GHS09

Wng

H361fd

H302

H410

oral: ATE = 780 mg/kg bw

M = 10

M = 10

613-282-00-0

triticonazole (ISO);

(RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol

—

138182-18-0

Repr. 2

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H361f

H373

H400

H410

GHS08

GHS09

Wng

H361f

H373

H410

M = 1

M = 1

613-329-00-5

halosulfuron-methyl (ISO);

methyl 3-chloro-5-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-1-methyl-1H-pyrazole-4-carboxylate

—

100784-20-1

Repr. 1B

Aquatic Acute 1

Aquatic Chronic 1

H360D

H400

H410

GHS08

GHS09

Dgr

H360D

H410

M = 1000

M = 1000

613-330-00-0

2-methylimidazole

211-765-7

693-98-1

Repr. 1B

H360Df

GHS08

Dgr

H360Df

613-331-00-6

(2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol;

mefentrifluconazole

—

1417782-03-6

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

M = 1

M = 1

613-332-00-1

oxathiapiprolin (ISO);

1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone

—

1003318-67-9

Aquatic Chronic 1

H410

GHS09

Wng

H410

M = 1

613-333-00-7

pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyridine-2(1H)-thionato-.kappa.S]zinc

236-671-3

13463-41-7

Repr. 1B

Acute Tox. 2

Acute Tox. 3

STOT RE 1

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H301

H372

H318

H400

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H360D

H330

H301

H372

H318

H410

inhalation: ATE = 0,14 mg/L (dusts or mists)

oral: ATE = 221 mg/kg bw

M = 1000

M = 10

613-334-00-2

flurochloridone (ISO);

3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one

262-661-3

61213-25-0

Repr. 1B

Acute Tox. 4

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H360FD

H302

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H360FD

H302

H317

H410

oral: ATE = 500 mg/kg bw

M = 100

M = 100

613-335-00-8

4,5-dichloro-2-octyl-2H-isothiazol-3-one; [DCOIT]

264-843-8

64359-81-5

Acute Tox. 2

Acute Tox. 4

Skin Corr. 1

Eye Dam. 1

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 1

H330

H302

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H314

H317

H410

EUH071

inhalation: ATE = 0,16 mg/L (dusts or mists)

oral: ATE = 567 mg/kg bw

Skin Irrit. 2; H315: 0,025 % ≤ C < 5 %

Eye Irrit. 2; H319: 0,025 % ≤ C < 3 %

Skin Sens. 1A; H317: C ≥ 0,0015 %

M = 100

M = 100

613-336-00-3

2-methyl-1,2-benzothiazol-3(2H)-one;

[MBIT]

—

2527-66-4

Acute Tox. 4

Acute Tox. 3

Skin Corr. 1C

Eye Dam. 1

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 2

H312

H301

H314

H318

H317

H400

H411

GHS06

GHS05

GHS09

Dgr

H312

H301

H314

H317

H410

EUH071

dermal: ATE = 1100 mg/kg bw

oral: ATE = 175 mg/kg bw

Skin Sens. 1A; H317: C ≥ 0,0015 %

M = 1

613-337-00-9

prothioconazole (ISO);

2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione

—

178928-70-6

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 10

M = 1

613-338-00-4

azamethiphos (ISO); S-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl] O,O-dimethyl thiophosphate

252-626-0

35575-96-3

Carc. 2

Acute Tox. 3

Acute Tox. 4

STOT SE 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H331

H302

H370 (nervous system)

H317

H400

H410

GHS06

GHS08

GHS09

Dgr

H351

H331

H302

H370 (nervous system)

H317

H410

inhalation: ATE = 0,5 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 1 000

M = 1 000

613-339-00-X

3-methylpyrazole

215-925-7

1453-58-3

Repr. 1B

Acute Tox. 4

STOT RE 2

Skin Corr. 1

Eye Dam. 1

H360D

H302

H373 (lung)

H314

H318

GHS08

GHS07

GHS05

Dgr

H360D

H302

H373 (lung)

H314

oral: ATE = 500 mg/kg bw

613-340-00-5

clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one

—

81777-89-1

Acute Tox. 4

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H400

H410

GHS07

GHS09

Wng

H332

H302

H410

inhalation: ATE = 4,85 mg/l (dusts or mists)

oral: ATE = 768 mg/kg bw

M = 1

M = 1

614-030-00-2

emamectin benzoate (ISO); (4"R)-4"-deoxy-4"-(methylamino) avermectin B1 benzoate

—

155569-91-8

Acute Tox. 3

Acute Tox. 3

Acute Tox. 3

STOT SE 1

STOT RE 1

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H331

H311

H301

H370 (nervous system)

H372 (nervous system)

H318

H400

H410

GHS06

GHS05

GHS08

GHS09

Dgr

H331

H311

H301

H370 (nervous system)

H372 (nervous system)

H318

H410

inhalation:

ATE = 0,663

mg/l (dusts or mists)

dermal:

ATE = 300

mg/kg bw

oral: ATE =

60 mg/kg bw

STOT RE 1; H372: C ≥ 5 %; STOT RE 2; H373: 0,5 % ≤ C < 5 %

M = 10 000

M = 10 000

616-014-00-0

butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime

202-496-6

96-29-7

Carc. 1B

Acute Tox. 4

Acute Tox. 3

STOT SE 3

STOT SE 1

STOT RE 2

Skin Irrit. 2

Eye Dam. 1

Skin Sens. 1

H350

H312

H301

H336

H370 (upper respiratory tract)

H373 (blood system)

H315

H318

H317

GHS08

GHS06

GHS05

Dgr

H350

H312

H301

H336

H370 (upper respiratory tract)

H373 (blood system)

H315

H318

H317

dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw

616-018-00-2

diethyltoluamide (ISO): N,N-diethyl-m-toluamide; [deet]

205-149-7

134-62-3

Acute Tox. 4

Skin Irrit. 2

Eye Irrit. 2

H302

H315

H319

GHS07

Wng

H302

H315

H319

oral:

ATE = 1892 mg/kg bw

616-032-00-9

diflufenican (ISO);

N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide; 2′,4′-difluoro-2-(α,α,α-trifluoro-m-tolyloxy) nicotinanilide

—

83164-33-4

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 10 000

M = 1 000

616-106-00-0

phenmedipham (ISO); methyl 3-(3-methylcarbaniloyloxy)carbanilate

237-199-0

13684-63-4

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 10

M = 10

616-113-00-9

desmedipham (ISO);

ethyl 3-phenylcarbamoyloxyphenylcarbamate

237-198-5

13684-56-5

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H400

H410

GHS08

GHS09

Wng

H361d

H410

M = 10

M = 10

616-225-00-8

(RS)-2-methoxy-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide; mandestrobin

—

173662-97-0

Aquatic Acute 1 Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1

M = 10

616-226-00-3

carboxin (ISO);

2-methyl-N-phenyl-5,6-dihydro-1,4-oxathiine-3-carboxamide; 5,6-dihydro-2-methyl-1,4-oxathiine-3-carboxanilide

226-031-1

5234-68-4

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H373 (kidneys)

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H373 (kidneys)

H317

H410

M = 1

M = 1

616-227-00-9

metaflumizone (ISO); (EZ)-2’-[2-(4-cyanophenyl)-1-(α,α,α -trifluoro-m-tolyl)ethylidene]-[4-(trifluoromethoxy)phenyl]carbanilohydrazide [E-isomer ≥ 90 %, Z-isomer ≤ 10 % relative content]; [1]

(E)-2’-[2-(4-cyanophenyl)-1-(α,α,α -trifluoro-m-tolyl)ethylidene]-[4-(trifluoromethoxy)phenyl]carbanilohydrazide [2]

—

139968-49-3 [1]

852403-68-0 [2]

Repr. 2

Lact.

STOT RE 2

H361fd

H362

H373

GHS08

Wng

H361fd

H362

H373

616-228-00-4

3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide;

fluxapyroxad

—

907204-31-3

Lact.

Aquatic Acute 1

Aquatic Chronic 1

H362

H400

H410

GHS09

Wng

H362

H410

M = 1

M = 1

616-230-00-5

N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA]

213-103-2

924-42-5

Carc. 1B

Muta. 1B

STOT RE 1

H350

H340

H372 (peripheral nervous system)

GHS08

Dgr

H350

H340

H372 (peripheral nervous system)

616-231-00-0

5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazole-4-carboxamide; 2'-[(RS)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide;

penflufen

—

494793-67-8

Carc. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 1

M = 1

616-232-00-6

iprovalicarb (ISO);

isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate

—

140923-17-7

Carc. 2

H351

GHS08

Wng

H351

616-233-00-1

silthiofam (ISO);

N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide

—

175217-20-6

STOT RE 2

Aquatic Chronic 2

H373

H411

GHS08

GHS09

Wng

H373

H411

616-234-00-7

N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen

—

1228284-64-7

Carc. 2

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H361f

H400

H410

GHS08

GHS09

Wng

H351

H361f

H410

M = 1

M = 1

616-235-00-2

N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane

—

874967-67-6

Carc. 2

Aquatic Acute 1

Aquatic Chronic 2

H351

H400

H411

GHS08

GHS09

Wng

H351

H410

M = 1

617-006-00-X

bis(α,α-dimethylbenzyl) peroxide

201-279-3

80-43-3

Org. Perox. F

Repr. 1B

Skin Irrit. 2

Eye Irrit. 2

Aquatic Chronic 2

H242

H360D

H315

H319

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H242

H360D

H315

H319

H411

648-055-00-5

Pitch, coal tar, high-temp.; [The residue from the distillation of high temperature coal tar. A black solid with an approximate softening point from 30 °C to 180 °C (86 °F to 356 °F). Composed primarily of a complex mixture of three or more membered condensed ring aromatic hydrocarbons.]

266-028-2

65996-93-2

Carc. 1A

Muta. 1B

Repr. 1B

H350

H340

H360FD

GHS08

Dgr

H350

H340

H360FD

650-056-00-0

dibutylbis(pentane-2,4-dionato-O,O’)tin

245-152-0

22673-19-4

Repr. 1B

STOT RE 1

H360FD

H372 (immune system)

GHS08

Dgr

H360FD

H372 (immune system)

650-057-00-6

Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide]

283-644-7

84696-25-3

Aquatic Chronic 3

H412

H412